ARTÍCULO DE REVISIÓN
REFERENCIAS BIBLIOGRÁFICAS
70
Rev méd panacea 2023 May-Ago;12(2): 63-71
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Laing R, Gillan V, Devaney E. Ivermectin - Old Drug, New
Tricks? Trends Parasitol. 2017 Jun;33(6):463-472. doi:
10.1016/j.pt.2017.02.004. Epub 2017 Mar 9.
Chosidow A, Gendrel D. [Safety of oral ivermectin in
children]. Arch Pediatr. 2016 Feb;23(2):204-9. doi:
10.1016/j.arcped.2015.11.002. Epub 2015 Dec 14.
González Canga A, Sahagún Prieto AM, Diez Liébana MJ,
Fernández Martínez N, Sierra Vega M, García Vieitez JJ.
AAPS J. The pharmacokinetics and interactions of
ivermectin in humans--a mini-review. 2008;10(1):42-6. doi:
10.1208/s12248-007-9000-9. Epub 2008 Jan 25.
Crump A. Ivermectin: enigmatic multifaceted 'wonder'
drug continues to surprise and exceed expectations. J
Antibiot (Tokyo). 2017 May;70(5):495-505. doi:
10.1038/ja.2017.11. Epub 2017 Feb 15.
Nagy P., Simon A. Nuevos conocimientos sobre los
mecanismos de recombinación de ARN. Virología
Volumen 235, Número 1 , 18 de agosto de 1997, Páginas
1-9. https://doi.org/10.1006/viro.1997.8681
Mishra SK, Tripathi T. One year update on the COVID-19
pandemic: Where are we now? Acta Trop. 2021
Feb;214:105778. doi: 10.1016/j.actatropica.2020.105778.
Epub 2020 Nov 28.
Gupta P, Goyal K, Kanta P, Ghosh A, Singh MP. Novel
2019-coronavirus on new year's Eve. Indian J Med
Microbiol. 2019 Oct-Dec;37(4):459-477. doi:
10.4103/ijmm.IJMM_20_54.
Callaway, E., 2020b. Making sense of coronavirus
mutations. Nature 585, 174–177.
Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J.
ICON (ivermectin in Covid nineteen) study: use of
ivermectin is associated with lower mortality in
hospitalized patients with COVID19. CHEST 2021;
159(1):85-92.
https://doi.org/10.1101/2020.06.06.20124461.
2020.06.06.20124461.
Lehrer S, Rheinstein PH. Ivermectin Docks to the
SARS-CoV-2 Spike Receptor-binding Domain Attached to
ACE2. In Vivo. 2020 Sep-Oct;34(5):3023-3026. doi:
10.21873/invivo.12134.
Schmith VD, Zhou J, Lohmer LR. The approved dose of
ivermectin alone is not
the ideal dose for the treatment of COVID-19. Clin
Pharmacol Ther. 2020 May.
https://doi.org/10.1002/cpt.1889
Peña-Silva R, Duffull SB, Steer AC, Jaramillo-Rincon SX,
Gwee A, Zhu X. Pharmacokinetic considerations on the
repurposing of ivermectin for treatment of COVID-19. Br J
Clin Pharmacol. 2020 Jul 17:10.1111/bcp.14476. doi:
10.1111/bcp.14476. Online ahead of print.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR.
Ivermectin and COVID-19: Keeping Rigor in Times of
Urgency. Am J Trop Med Hyg. 2020 Jun;102(6):1156-1157.
doi: 10.4269/ajtmh.20-0271.
Georgi Momekov & Denitsa Momekova (2020) Ivermectin
as a potential COVID-19 treatment from the
pharmacokinetic point of view: antiviral levels are not likely
attainable with known dosing regimens, Biotechnology &
Biotechnological Equipment, 34:1, 469-474, DOI:
10.1080/13102818.2020.1775118
Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of
Ivermectin Alone is not the Ideal Dose for the Treatment of
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
COVID-19. Clin Pharmacol Ther. 2020 Oct;108(4):762-765.
doi: 10.1002/cpt.1889. Epub 2020 Jun 7.
Li N, Zhao L, Zhan X. Quantitative proteomics reveals a
broad-spectrum antiviral property of ivermectin,
benefiting for COVID-19 treatment. J Cell Physiol. 2021
Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020
Sep 22.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD,
Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J,
Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A
five-day course of ivermectin for the treatment of
COVID-19 may reduce the duration of illness. Int J Infect
Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191.
Epub 2020 Dec 2.
Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A,
Hurtado JC, Subirà C, Grau-Pujol B, Krolewiecki A, Muñoz J.
Lack of efficacy of standard doses of ivermectin in severe
COVID-19 patients. PLoS One. 2020 Nov
11;15(11):e0242184. doi: 10.1371/journal.pone.0242184.
eCollection 2020.
Chaccoura, et. al. The effect of early treatment with
ivermectin on viral load, symptoms and humoral response
in patients with non-severe COVID-19: A pilot,
double-blind, placebo-controlled, randomized clinical trial.
https://doi.org/10.1016/j.eclinm.2020.100720
López-Medina E, López P, Hurtado C, Dávalos D. Ramirez
O, Martínez E. et al. Effect of Ivermectin on Time to
Resolution of Symptoms Among Adults With Mild
COVID-19. JAMA Published online March 4, 2021.
doi:10.1001/jama.2021.3071
Rizzo E. Ivermectin, antiviral properties and COVID-19: a
possible new mechanism of action. Arch Pharmacol. 2020
Jul;393(7):1153-1156. doi: 10.1007/s00210-020-01902-5.
Epub 2020 May 27.
Gupta D, Sahoo AK, Singh A. Ivermectin: potential
candidate for the treatment of Covid 19. Braz J Infect Dis.
2020 Jul-Aug;24(4):369-371. doi:
10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28.
Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR,
Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ,
Leblebicioglu H. Ivermectin, a new candidate therapeutic
against SARS-CoV-2/COVID-19. Ann Clin Microbiol
Antimicrob. 2020 May 30;19(1):23. doi:
10.1186/s12941-020-00368-w.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020
Apr) The FDA-approved Drug Ivermectin inhibits the
replication of SARSCoV-2 in vitro. Antiviral Res. 3:104787
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin
and COVID-19: A report in Antiviral Research, widespread
interest, an FDA warning, two letters to the editor and the
authors' responses. Antiviral Res. 2020 Jun;178:104805.
doi: 10.1016/j.antiviral.2020.104805. Epub 2020 Apr 21.
Carlosama-Rosero Y. Ivermectin in COVID-19. Argumentun
ad ignorantiam? Rev Clin Esp. 2020 Oct;220(7):457-458.
doi: 10.1016/j.rce.2020.06.003. Epub 2020 Jun 12.
Kirti R, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B et al.
Ivermectin as a potential treatment for mild to moderate
COVID-19: A double blind randomized placebo-controlled
trial. [Preprint]. 9th January 2021. Medrxiv. doi:
https://doi.org/10.1101/2021.01.05.21249310
Hashim H, Maulood M, Rasheed A, Fatak D, Kabah K,
Abdulamir A. Controlled randomized clinical trial on using
Revisión sistemática sobre efectos de la Ivermectina sobre COVID-19